Get started
Author

Mohammed Bajji

Observed name: M. Bajji
OpenAlex ID: A5069326770
What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
2021 · Sara Pizzamiglio, Giulia Cosentino, et al. · Cancer Medicine · 10
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
2023 · Serena Di Cosimo, Chiara M. Ciniselli, et al. · Frontiers in Oncology · 7
PDF
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer
2026 · Soraia Lobo-Martins, Diogo Martins-Branco, et al. · Frontiers in Immunology · 1
PDF
531TiP ZEPHIR-02 trial: HER2-PET/CT with 89Zr-trastuzumab to guide antibody–drug conjugate sequencing in advanced HER2-positive breast cancer, post-progression on T-DXd
2026 · S. Lobo-Martins, G. Nader Marta, et al. · ESMO Open
PDF
140P I-SPARC trial: Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients (pts) with cancer
2025 · S. Lobo-Martins, D. Martins-Branco, et al. · Immuno-Oncology Technology
Abstract 1229: miRNA and response to trastuzumab
2022 · Giulia Cosentino, Sara Pizzamiglio, et al. · Cancer Research
Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study
2022 · Marilena Valeria Iorio, Sara Pizzamiglio, et al. · Cancer Research
Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial
2020 · Mattia Rediti, David Venet, et al. · Cancer Research
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.
2020 · Mattia Rediti, David Venet, et al. · Journal of Clinical Oncology
Works count: 9
Citation count: 18
H-index: 2
I10-index: 1
Year
Topic
Type